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THE ROLE OF PTEN IN HUMAN CANCER 
Phosphatase and tensin homolog, PTEN, is a key tumor suppressor. 
Mutation of PTEN is associated with both sporadic cancers and a cluster of 
familial cancer predisposition syndromes called PTEN hamaratoma syndromes.  
These germline mutations span the length of the PTEN gene with a mutational 
hot spot localized in exon 5. This exon encodes the catalytic domain of PTEN, 
which is critical for its tumor suppressor activity. PTEN function is most 
commonly attributed to lipid phosphatase activity on Phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) that leads to inhibition of a cascade with downstream pro-
survival effectors including Akt, but PTEN also has phosphatase activity on a 
small number of proteins. Recently, a mutation, G129E, has been described as a 
gain of function (GOF) mutation in PTEN knockin mice.  This mutant only retains 
protein phosphatase activity while it completely lacks lipid phosphatase activity.  
Collectively (in the mouse and in vitro studies), there is no clear mechanism to 
explain the GOF nature of this mutant. Understanding how mutants of PTEN 
function in the cells to provide a growth advantage will provide insight into what 
pathway to therapeutically target. Our central hypothesis is that mutations of 
PTEN promote tumorigenesis through gain of function activities that result in cell 
cycle progression. We will determine the signaling pathways that are affected by 
the gain of function mutant PTEN G129E to better understand the mechanism by 
which mutants of PTEN confer a growth advantage. 
Lindsey D. Mayo, PhD, Chair 
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INTRODUCTION 
Cancer is a disease in which our very own genes become mutated in a 
way that give an evolutionary advantage through various means over the 
surrounding normal cells. This advantage gives cells the ability to grow 
uncontrollably in unique ways to each and every cancer. In the mid 1800s John 
Bennett and Rudolf Virchow independently discovered the increased numbers of 
white blood cells in two patients. Bennett attributed the increase in white blood 
cells to an infection while Virchow developed a different theory. Virchow 
proposed, knowing that we are all made of cells that these cells must arise from 
cells. Furthermore, the increase in white cells he was seeing must be either from 
an increase in size that he termed hypertrophy or an increase in cell number 
termed hyperplasia. Virchow named the illness leukemia and was the first to 
define cancer as an abnormal replication of cells. This new realization could be 
applied to solid tumors as well (Degos, 2001). 
Although abnormal cell growth can be simply said, cells are complex 
machines that have many means of both regulating growth and senescence. 
Naturally, cells have genes that produce proteins that function to suppress 
growth and division as a means of protecting the cell when conditions are not 
favorable, and these are called tumor suppressors. Conversely, proto-oncogenes 
are genes that upon mutation or other means of regulation produce proteins that 
cause the cell to grow and divide despite signaling that it should not. In the 
mutated state these are referred to as oncogenes (Varmus, Pao, Politi, 
Podsypanina, & Du, 2005). 
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There are a couple of ways normal genes become oncogenes and 
similarly ways in which tumor suppressors no longer guard cells against cancer. 
Hermann J. Muller helped to define these means and named them morphs 
(Muller, Carlson, & Schalet, 1961) . Oncoproteins or oncogenes are generally 
hypermorphs, antimorphs, or neomorphs. Hypermorphs are ways in which genes 
gain function either through gene dose, expression, or constitutive activity. 
Antimorphs are genes that are expressed as dominant negative proteins, and 
neomorphs are genes that express proteins that have completely different 
functions than the wild type protein. Tumor suppressors are affected by 
mutations usually to hypomorphs or amorphs. Hypomorphs are cases where 
genes lose partial function, and amorphs are where genes completely lose 
function (Muller et al., 1961). 
In an attempt to clarify way in which cancer maintains abnormal growth 
and to define cancer, Hanahan and Weinberg delineated six pathways by which 
cells maintain carcinogenic signaling and deemed it the hallmarks of cancer 
(Hanahan & Weinberg, 2000). 
1. “Self sufficiency in growth signals” 
In normal homeostatic states, cells respond to growth signaling with 
proliferation. These forms of growth signaling can include ligand growth 
factors, cell-cell adhesions, or intracellular matrix interactions. A cancerous 
cell avoids the need for these growth signals by autocrine feedback loops 
(Alimandi et al., 1997), overexpression of receptors (Slamon et al., 1987; 
Yarden & Ullrich, 1988), mutated to constitutively active receptors (Alimandi 
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et al., 1997), and switching to more growth prone extracellular matrix 
proteins (Lukashev & Werb, 1998). 
2. “Evading apoptosis” 
Cancerous cells avoid programmed cell death by downregulation or inhibition 
of cell sensors or effectors involved in recognition or initiation of cell death 
signaling. Normal cells regulate apoptosis, or programmed cell death, by 
both internal signals as well as external signals. For instance cell death 
signals are the Fas ligand/receptor, and the TNFα (Tumor Necrosis Factor) 
and the TNF receptor and activate apoptosis under unfavorable extracellular 
conditions (Ashkenazi & Dixit, 1999). Conversely, signaling imbalances, DNA 
damage, and hypoxia can also initiate apoptosis (Evan & Littlewood, 1998).  
3. “Insensitivity to antigrowth signals” 
Cells use anti-growth signaling to inhibit proliferation in states where growth 
is not favored. For example, the cell is heavily regulated by the cell cycle. 
Most notably, pRB or retinoblastoma protein is a tumor suppressor that is 
heavily regulated by phosphorylation from Cyclin Dependent Kinases (CDK) 
when conditions are met for cell cycle to progress. When pRb is 
hyperphosphorylated, it releases E2F, which is a transcription factor that 
allows for the production of cell cycle machinery including cyclins E and A.  
In certain cancers pRb is lost genetically or by mutation and is therefor 
unable to bind E2F or prevent transcription of necessary cyclins to pass 
through the cell cycle (Weinberg, 1995)(Figure 1).  
4. “Sustained angiogenesis”  
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Considering the necessities that blood vessels are to carry oxygen and 
nutrients and provide a system for waste removal, it is essential for a tumor 
to maintain close proximity to functioning vasculature. Tumors are known to 
modulate vasculature formation by increasing transcription factors of pro-
angiogenic factors like Vascular Endothelial Growth Factor (VEGF) and 
Fibroblast growth factor (FGF) (Cheung, Singh, Ebaugh, & Brace, 1995; 
Gately et al., 1997; Volpert, Dameron, & Bouck, 1997). 
5. “Limitless replicative potential” 
Hayflick first observed that cells have a limited number of divisions and the 
point at which this limit is reach he deemed the Hayflick limit (Hayflick, 1997). 
Furthermore, this limit is mediated by telomeres, or nucleotide repeats at the 
ends of telomeres that shorten with each division as a means of protecting 
genes from incomplete replication at the ends of chromatids and engaging 
senescence when the telomeres have become too short. In cancer, an 
enzyme known as Telomerase becomes activated and lengthens telomeres 
such that they may continue dividing (Hayflick, 1997). 
6. “Tissue evasion and Metastasis” 
Metastasis is the leading cause of mortality in human cancer. In order for 
cancer to metastasize, it must undergo certain changes to mobilize from the 
primary tumor. Epithelial to mesenchymal transition (EMT) is a process in 
which cells lose polarity, and cell-cell adhesions to gain motility. Metastatic 
cancers often express SNAIL, Twist, or ZEB1, which are drivers of EMT. 
Additionally, when a tumor cell reaches its secondary site, it must undergo 
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mesenchymal to epithelial transition (MET) to regain polarity and cell-cell 
contacts to form a secondary or metastatic tumor (Grivennikov, Greten, & 
Karin, 2010). 
 Once cancer is characterized, particular pathways begin to emerge. The 
cell cycle is an essential regulator of growth and division, and in many cases is 
manipulated in cancer. The cell cycle combines extracellular and intracellular 
signaling to determine if the cell has the resources and necessary conditions to 
divide. Cell cycle regulators sense the amount of DNA damage, replication 
machinery, growth factors, mitotic machinery, and the availability of oxygen and 
translate those signals into appropriate transcription of proteins to carry out the 
cell cycle.  
 During the mammalian cell cycle, growth factors induce cells to leave the 
quiescent stage (G0) to growth stage one (G1). In the early stage of G1, Rb 
becomes hyperphosphorylated and looses affinity for the transcription factor, 
E2F. When E2F is responsible for induction of many gene including cyclin E and 
cyclin A, which are involved in the progression to synthesis (S) and growth stage 
two (G2). During S phase, E2F is then phosphorylated and degraded (Mudryj et 
al., 1991). Rb remains hyperphosphorylated through S, G2, and metaphase (M) 
(Lin & Wang, 1992). Cyclin B levels are increased in M, cyclin D and E are 
increased in G1, and cyclin A levels are increased in G2 and S (Breeden, 2000). 
These cyclins are active when bound to appropriate cyclin dependent kinases 
(Zhu, Ohtsubo, Bohmer, Roberts, & Assoian, 1996). Aside from regulation by 
transcription, and binding partner cyclin dependent kinases, additional regulation 
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exists. Cdc25 is a phosphatase involved in the activation of CDK1/Cyclin B 
complexes by dephosphorylation of the tyrosine 14 and 15, after Cyclin-
dependent activating kinase (CAK) phosphorylates threonine 161 on the CDK. 
This allows the CDK1/Cyclin B cell to pass from interphase to mitosis (Gabrielli, 
Lee, Walker, Piwnica-Worms, & Maller, 1992). Cell cycle inhibitors fall into two 
classes: the CIP/KIP tertiary family inhibitors and the INK4 family binary 
inhibitors. Within the class of CIP/KIP inhibitors is p21, p27, and p57 (Hengst & 
Reed, 1998).  Loss of p27 is more commonly associated with cancer than the 
p21 and p57 (Esposito et al., 1997). As an inhibitor of the cell cycle p27 is lost 
under growth conditions and is also often lost in cancer. Src phosphorylates p27 
at tyrosine 74. An additional phosphorylation by cyclin E or A/CDK2 targets p27 
for proteolytic degradation (Chu et al., 2007)(Figure 1).  
 The cell cycle is just one pathway in a network of pathways involved in 
human cancer. p53 is one protein that bridges many types of stress signaling 
with the cell cycle. As the most commonly lost tumor suppressor in human 
cancer, it is pivotal in pausing the cell cycle for moderate damage so that DNA 
repair can occur (Berger, Vogt Sionov, Levine, & Haupt, 2001). If the DNA 
damage is beyond the threshold of repair p53 can initiate apoptosis (Chiarugi, 
Magnelli, & Cinelli, 1997). Under normal growth conditions, activated PI3K 
pathway leads to and activated Akt. Akt phorphorylates Mdm2 allowing it to 
translocate to the nucleus bind p53 and facilitate its nuclear export (Hu, Feng, & 
Levine, 2012). Ubiquitinated p53 that is cytoplasmic localized renders p53 to be 
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polyubiqutinated and subsequently targeted for proteasomal degradation (Honda, 
Tanaka, & Yasuda, 1997; Mayo & Donner, 2001). 
 Among the most commonly altered pathways in human cancer are the 
receptor tyrosine kinase (RTK), Mitogen-activated protein kinase (MAPK), PIP3 
kinases, Ras, and p53 pathways. It becomes clear from the initial overview that 
kinase signaling is key in cancer pathways.   
 Beginning at the membrane, RTKs are transmembrane proteins that exist 
as monomers but upon activation by growth factors, hormones, or cytokines, 
dimerize with nearby monomers. RTKs have a highly conserved extracellular N-
terminus that binds ligands, a transmembrane region, and a C-terminal region 
containing the kinase domain. Dimerization initiates a transphosphorylation event 
whereby both monomers become tyrosine phosphorylated. These 
phosphorylation events then prime the receptor for binding with the Src homology 
domain 2 (SH2) of binding partners, and activate the kinase for signal 
transduction through many pathways within the cell. HER2 or ERBB2 is 
overexpressed in some human breast cancers as a result a modest level of 
epidermal growth factor (EGF), may have a robust effect on downstream signal 
transduction (Marshall, 1995). 
 Within the cell, other kinases take over signaling. Src activated by RTKs. 
v-Src, or viral Src, was first discovered by Peyton Rous in cell free chicken 
extracts, that could induce cancer when injected into healthy chickens. Peyton 
Rous had isolated the Rous Sarcoma Virus (RSV), and thought that it could be 
the origin of all of cancer (Rous, 1960). Unfortunately, many other oncoproteins 
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exist and this was only the beginning of the understanding of cancer. Later it was 
isolated by John Michael Bishop and Harold E. Varmus who determined that Src 
was a human gene that had been hijacked and mutated by the Rous Sarcoma 
virus (Varmus et al., 2005). Src can be activated by many receptors, these 
include RTKs, Insulin-like growth factor receptor 1 (IGFR-1), Human epidermal 
growth factor receptor (HER2), and Epidermal growth factor receptor (EGFR) (S. 
Zhang et al., 2011). Src, unlike RTKs, is an intracellular tyrosine kinase 
composed of three main functional domains. The protein structure of Src 
contains: Src homology 2 domain (SH2); the Src homology 3 domain (SH3); and 
the kinase domain. The SH2 domain is a docking domain that binds to multiple 
other proteins like RTKs when they are tyrosine phosphorylated (Lammers et al., 
1993). The SH3 domain is an adapter domain necessary for mediating complex 
formation. Finally, the kinase domain is the functional tyrosine kinase. The 
activation and inactivation of Src has been well defined. When inactivated, the 
SH3, SH2 and kinase domain are bound in a closed conformation with a 
phosphorylation at tyrosine 527 on the c-terminal tail. Upon docking to a receptor 
at the SH2 domain, Protein tyrosine phosphatase non-receptor type 11 (Shp2) 
dephosphorylates tyrosine 527. This dephosphorylation triggers a conformational 
change and an autophosphorylation results in a phosphorylation at tyrosine 416 
(Irby & Yeatman, 2000)(Figure 2). This combination of events results in an active 
kinase that induces signal transduction on many targeted pathways including 
Focal Adhesion kinase (FAK), Protein kinase C (PKC), Signal transducer and 
activator of transcription 3 (STAT3), and Mitogen-activated protein kinase 
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(MAPK) (S. Zhang et al., 2011).  Considering the robust signals that can result 
from Src, especially in the cases of cancer where receptors are overexpressed or 
Src is constitutively active it is critical to understand the inactivation of Src. When 
Src is in the active conformation, C-terminal Src Kinase (CSK) docks at the c-
terminus, and allows a protein tyrosine phosphatase to bind and dephosphorylate 
tyrosine 416. The protein tyrosine phosphatase then unbinds and then CSK 
phosphorylates tyrosine 527. The c-terminal tail returns to the closed 
conformation on the SH2 domain. At this point the CSK unbinds and Src is 
completely inactive (Ayrapetov et al., 2006)(Figure 3). 
 The Ras subfamily is a group of small GTPases that is an activator of 
proliferation. It was discovered similarly to Src, but from Rat Sarcoma virus. Ras 
is a G-protein involved in converting guanosine triphosphate (GTP) to guanosine 
diphosphate (GDP). When GTP is bound, Ras is in the active “on” confirmation 
and “off” when GDP is bound. In the active conformation Ras can activate 
Rapidly accelerating fibrosarcoma (Raf) and Phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K). Ras generally has low intrinsic activity for 
hydrolyzing GTP to GDP, so it recruits guanosine activating proteins (GAPs) 
under normal conditions. Conversely, guanosine exchange factors (GEFs) are 
necessary for swapping GDP for GTP and restoring Ras to the active 
conformation. In cancer, Ras can be mutated to be constitutively active or Ras-
GAPs can be lost and Ras is less frequently inactivated (Bos, 1989).  
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 In cancer an active Ras activates Raf, MEK, and ERK a serine/threonine 
kinase cascade that protects cell survival through activation of transcription of 
pro-survival genes (Bos, 1989).  
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathways can both 
be activated by Ras. Canonical function of the PI3K pathway involves activation 
of a receptor tyrosine kinase by an extracellular ligand. PI3K actively converts 
PIP2 to PIP3. The increase in PIP3 near the membrane causes an increase in 
recruitment of Protein Kinase B (Akt) and Protein Dependent Kinase (PDK) 
localization to the membrane. PDK is the activating kinase for Akt, thus their co-
localization allows for activation of Akt. Akt is a commonly activated in human 
cancers as it has robust pro-growth and angiogenic downstream pathways 
including: VEGF, Mdm2, and mTOR.  
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) or 
Mutated in Multiple Advanced Cancers (MMAC) was named for being lost in 
advanced cancers and its homology to Protein Tyrosine Phosphatase (PTP) (Li 
et al., 1997; Steck et al., 1997)(Figure 4). PTEN acts to dephosphorylate PIP3 to 
PIP2 at the D3 phosphate thereby inhibiting the subcellular localization of PDK 
and Akt and subsequent activation. Activation of the Akt pathway is usually under 
control of growth factors and growth factor receptors but can be hijacked in 
cancer cells when the inhibitory activity of PTEN is lost (Maehama, Okahara, & 
Kanaho, 2004; Myers et al., 1998)(Figure 5).   
PTEN is known to bind p53 and is a transcriptional target of p53(refs 
Stamblolic work and Mayo in Jbc) The PTEN-p53 complex can targets gene 
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expression that may induce cell cycle arrest or apoptotic genes in response to 
DNA damage (Chiarugi et al., 1997; Haapajarvi, Kivinen, Pitkanen, & Laiho, 
1995). Similarly, PTEN complexes with p73 inducing Puma and Bax, which 
initiates apoptosis (Lehman et al., 2011)(Figure 6).  
In addition to being lost in many advanced cancers, PTEN was found 
mutated in cancer predisposition syndromes such as Cowden’s syndrome (Liaw 
et al., 1997).  
PTEN is a 403 amino acid protein composed of an N-terminus, a 
phosphatase domain, a C2 domain, a C-terminal tail, and a PDZ binding domain. 
There is only a single catalytic site known to exist in the phosphatase domain. 
The PDZ binding domain is believed to be involved in membrane targeting. The 
C2 domain is highly conserved and considered to be an important location for 
post-translational modifications (Lee et al., 1999)(Figure 4). 
PTEN is also a heavily regulated protein, posttranslationally. It has 7 
phosphorylation sites on the c-terminal tail that when phosphorylated have been 
shown to give stability to PTEN but also inhibits PTEN activity. These sites are 
phosphorylated by casein kinase 2 (CK2), ATM, and glycogen synthase kinase 3 
beta (GS3Kβ) (Adey et al., 2000; Al-Khouri, Ma, Togo, Williams, & Mustelin, 
2005; Okamura et al., 2006)(Figure 4). 
Additionally the C2 domain can be phosphorylated by Rho associated 
protein kinase (ROCK) and the tyrosine kinase Rak which act to dissociate PTEN 
from the membrane (Fragoso & Barata, 2014)(Figure 4). 
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Sumoylation and ubiquitination of PTEN is still being delineated but it is 
clear that multiple sites are sumoylated and at least on is ubiquitinated. These 
large posttranslational modifications are involved with nuclear targeting (Lang et 
al., 2014)(Figure 4). 
Lysine acetyltransferase 2B (PCAF) acetylates PTEN on lysine 125 and 
lysine 128 and this reduced catalytic activity. An additional acetylation site is at 
lysine 402 is acetylated by CREB binding protein (CBP) and it may affect how it 
binds with partners in the PDZ binding domain (Ikenoue, Inoki, Zhao, & Guan, 
2008; Okumura et al., 2006)(Figure 4).  
By determining both the regulation of PTEN subcellular localization and its 
phosphatase activity, we may begin to understand the role of PTEN in human 
cancers. PTEN was initially determined to function by counteracting the 
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway by 
dephosphorylating Phosphatidylinositol (3,4,5)-trisphosphate (PIP3)(Figure 5).  
Initial experiments with recombinant protein and phosphatase assays by 
Myers et al. show that wild type PTEN has activity on small acidic peptides in 
addition to lipid phosphatase activity (Myers et al., 1997). This opened up the 
possibility for functions of PTEN. Gradually discoveries of protein targets 
occurred, as endogenous phosphatase activity was seen on FAK, and Shc in the 
cytoplasm. Shc and FAK were found physically interacting with PTEN, and both 
had decreased phosphotyrosine phosphorylation in the presence of PTEN. 
Downstream function of activity PTEN on these substrates led to decreased cell 
migration (J. Gu et al., 1999; Tamura et al., 1998). 
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In addition to having protein targets, it has become clear that PTEN not 
only localizes to the nucleus but is functional in the nucleus. Nuclear targets 
include CREB, which has been shown in complex with and dephosphorylated by 
PTEN at a site phosphorylated by active Akt, serine 133 (RRPSYRK) (T. Gu et 
al., 2011)(Figure 9). 
Furthermore, PTEN has been found in complex with the Anaphase 
promoting complex/cyclosome (APC/C) and is thought to be involved in allowing 
APC/C to bind with CDH1 allowing ubiquitin-mediated degradation of kinases 
and cyclins facilitating inhibition of the cell cycle. Interestingly this function is not 
dependent on phosphatase activity. (Manchado, Eguren, & Malumbres, 2010). 
PTEN has also been found in complex with centromere binding protein C, and 
has been shown to be important in double stranded break repair as it can cause 
the induction of RAD51. It is unknown if RAD51 induction or function involving 
centromere binding protein C are the cause, but MEFs lacking PTEN have 
chromosomal instability. Thus PTEN is involved in chromosomal instability 
through an unknown means. 
While the lipid phosphatase activity on PIP3 has been delineated into a 
clear mechanism, considerably less is known about how PTEN regulates 
proteins or how regulation of PTEN localization dictates its action on protein 
targets. The PTEN mutant PTENG129E has been shown to act specifically on 
proteins and not on lipids. Thus, it does not act on PIP3 to downregulate the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway because it is 
believed to have a shallower pocket in its phosphatase domain (Lee et al., 1999). 
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Similarly, it has been shown to have a gain of function (GOF) phenotype (Wang 
et al., 2010). While G129E isn’t the only PTEN mutant that has protein 
phosphatase activity, it is the only mutant that no longer retains lipid phosphatase 
activity. PTENM134L has increased protein phosphatase activity with respect to 
wild type PTEN but also retains lipid phosphatase activity. PTENG129E is a 
valuable tool because it lacks the canonical PTEN lipid phosphatase function 
allowing us to study functions independently. To date, no mutant has been 
discovered that retains lipid phosphatase activity but not protein phosphatase 
activity (Myers et al., 1997)(Figure 7 and 8).   
G129E is an interesting PTEN mutant that may gain tumorigenic potential 
through increased phosphatase activity on a target that it shares in common with 
wild type PTEN or a completely novel target. We wish to determine the pathways 
by which mutant PTENG129E gains a growth advantage over wild type PTEN as 
well as how regulation of PTEN is altered by post-translational modifications.  
Cancer predisposition syndromes and sporadic cancers are well-defined 
clinically, but generally poorly understood biochemically. Having a PTEN 
mutation until now has been viewed as having merely a passenger mutation or 
loss of a tumor suppressor in the context of another driver mutation. In certain 
tumors, mutated PTEN may actually be the driver, leaving little meaning to its 
known role as a “tumor suppressor”.  Both PTEN function (as a phosphatase) 
and subcellular localization are important in preventing tumorigenesis, but little is 
known about how signaling arises to change PTEN subcellular localization or 
how PTEN catalytic activity is regulated toward particular targets.  
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Recently a mutant PTEN, PTENG129E, has been defined as a gain of 
function (GOF) mutation based upon its phenotype in knockin mice. These mice 
develop more tumors than those expressing catalytically dead PTEN, or mice 
lacking PTEN. Only mutant PTENG129E mice had mammary tumors. Interestingly, 
this finding has been validated, as human patients with the PTENG129E Cowden’s 
syndrome, are more likely than other patients with catalytically dead PTEN to 
have breast cancers (Bassi et al., 2013). The gain of function theory was first 
hypothesized when certain p53 mutations seemed to have more tumorigenic 
potential than when there was no p53 at all. This is considered to be due to a 
dominant negative homodimerization that has activity on an increased number of 
cell cycle transcriptional targets. Similarly, wild type PTEN has recently been 
shown to dimerize in its wild type state and with PTENG129E (Papa et al., 2014). 
The mutant PTENG129E specifically retains protein phosphatase activity but no 
lipid phosphatase activity. Therefore this phosphatase activity could be increased 
or be operating on different targets compared to wild type PTEN that then 
promotes proliferation and cell cycle progression.  
We believe that PTEN does not always function as a tumor suppressor but 
an oncoprotein, and elucidating a mechanism by which mutant PTENG129E 
overcomes cell cycle checkpoints to propagate cancer may reveal a reasonable 
treatment approach with PTEN inhibitors that are already in development (De 
Paula, Cui, Hossain, Antel, & Almazan, 2014; Schmid, Byrne, Vilar, & 
Woscholski, 2004; Walker & Xu, 2014). Similarly, understanding what roles 
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nuclear translocation plays in cell cycle may open up new treatment approaches 
for individuals with mutations outside of the PTEN catalytic domain.  
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MATERIALS AND METHODS 
Cell Culture  
Cell culture was performed in Dulbecco’s modified Eagle’s medium 
(DMEM)(Life Technologies) with 10% fetal bovine serum (FBS) and 1,000 
units/ml penicillin-streptomycin (HyClone) solution at 37°C.  The incubator was 
humidified with 5% CO2 (Darnell, Levintow, & Scharff, 1970). 
 
Transfections 
Cells were transfected using the Polyethylenimine (PEI) method or 
Lipofectamine (Invitrogen)(Dalby et al., 2004).  PEI transfections were performed 
by mixing PEI, obtained from Clark Wells, in a 1 µg PEI: 1 µg plasmid DNA in 
300µl serum free media, followed by a 5 minute incubation period at room 
temperature. The PEI mixture was then added to the cells and incubated 
overnight and harvested for protein (Werth et al., 2006). Plasmid DNA was 
dependent on the size of the plate transfected, 5-6µg plasmid DNA was used for 
60mm plates and 10-12µg was used for 100mm plates. Lipofectamine 
transfections were done according to manufacturer’s protocol.  
 
Purification of recombinant proteins  
Escherichia coli (BL-21 or Rosetta) were transformed using 
manufacturer’s guidelines, and grown overnight in 50ml culture for Luria broth 
(LB) under chloramphenicol selection. From this a 10% glycerol stock was made 
in a 1ml cryo-tube and stored at -80°C for later use. A 200ml culture of LB was 
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inoculated with 50µg/ml ampicillin and grown overnight at 150RPM at 37°C. In 
the morning, the culture was diluted with LB to 0.2 OD and then grown to 
between 0.4 OD to 0.6 OD. The culture was induced to product proteins with the 
addition of 1mM of Isopropyl-β-D-thio-galactoside (IPTG). Induction continued for 
4-6 hours at the same temperature and RPM. Cells were spun down at 6000 
RPM for 20 minutes and resuspended in 1X Phosphate Buffered Saline (PBS), 
1% TritonX-100, 5mM DTT, and sonicated on ice. Debris was pelleted and the 
supernant was collected. Proteins were then subjected to glutathione sepharose 
using the Duo-Flow chromatography system from Bio-Rad.  Protein was eluted 
from the column using 1mm glutathione. The eluted protein fractions were run on 
an SDS PAGE gel. The gel was stained with Coomassie Brilliant Blue R-250 
stain (50%methanol:10% glacial acidic) for 20 minutes then destained in 50% 
methanol:10 glacial acidic acid). Fractions containing the corresponding bands 
were then collected and dialyzed overnight at 4°C in dialysis buffer (50mM Tris 
titrated to pH 7.5, 50mM NaCl, and 1mM DTT). 
 
Protein analysis, immunoprecipitation, and Western blotting 
Urea lysis buffer (20mM Tris, pH 6.8, 100mM sodium pyrophosphate, 6M 
urea) and a 2 second sonication on ice was used to lyse cells for whole cell 
extracts. A different lysis buffer was used for  immunoprecipitation or GST 
pulldown. IGEPAL lysis buffer (25mM Tris, pH 8.0, 150mM NaCl, 1% IGEPAL, 
Protease Cocktail (Sigma) 1:100, 1mM sodium orthovanadate), and followed by 
2 seconds of sonication on ice. The supernatant collected after centrifugation.  
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Protein concentration was determined using the supernatant and the use 
of Bradford Reagent (BioRad) per manufacturer’s instructions.  
For immunoprecipitation assays 500µg of lysates were incubated for 2 
hours at 4 °C with 2µg of antibody in 1ml of lysis buffer and 25µl of Protein A or 
Protein G Agarose (Pierce). The precipitates spun out of solution by 
centrifugation, the supernate was removed and the pellet was resuspended in 
lysis buffer. The pellets were subjected to three rounds of this procedure. 
Laemmli dye was added and boiled for 10 minutes and subjected to sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE). 
Polyacrylamide gel was transferred overnight onto polyvinylidene fluoride 
(PVDF) membrane at 100mA. Upon transfer, PVDF was blocked with 5% nonfat 
dry milk in PBST (phosphate buffered saline with 0.5% Tween 20 for one hour 
while rocking. Primary antibody was added at the defined dilution for one hour. 
The membrane was washed with PBST 3 times. Secondary antibody, specific to 
species, was applied to the membrane in PBST at 1:10,000 dilution for 45 
minutes followed by 3 washes, 10 minutes each. Enhanced chemiluminescence 
(ECL) was then applied and subjected to autoradigraph.  
 
Cell cycle analysis 
U87 cells were subjected to a 24 hour serum starvation, followed by 
varying treatments of 10% serum replacement, harvested and resuspended in 
PBS. Following a wash in PBS the cells were resuspended in 300 µl of 70% 
ethanol and 10µl Muse Cell Cycle Reagent from Millipore. Fixation was allowed 
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to take place overnight at 4 °C in the dark and the samples were run on the Muse 
Cell Analyzer according to manufacturer’s instruction. 
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RESULTS 
PTEN is a dual specificity phosphatase with activity on lipids and proteins 
(Myers et al., 1997). Early in the history of cancer research, PTEN was 
determined to have significant effects on tumorigenesis through its phosphatase 
activity on phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to 
phosphatidylinositol (3,5)-bisphosphate (PIP2), which antagonizes the 
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway that activates 
protein kinase B (Akt) with numerous downstream pro-growth, pro-angiogenic, 
and anti-apoptotic downstream effectors (Li et al., 1998)(Figure 5). However, 
PTEN has been shown to act on multiple protein targets (T. Gu et al., 2011). The 
PTEN mutant PTENG129E has been shown to be null for lipid phosphatase activity 
but retain protein phosphatase activity (Myers et al., 1997)(Figure 7 and 8). This 
provides a model to study the protein phosphatase activity independently of the 
lipid phosphatase activity. A PTENG129E knockin mouse has significantly more 
tumors in diverse organs than the catalytically dead PTEN mutant (Wang et al., 
2010).  In addition, the mutant PTENG129E mice develop mammary tumors. 
Clinicially the PTENG129E mutant was found to associate with breast cancer 
(Wang et al., 2010). However, in vitro or in vivo studies did not demonstrate how 
PTENG129E was mechanistically promoting tumor progression. We show here that 
expression of PTENG129E in cells leads to a growth advantage through specific 
modulation of cell cycle checkpoints. 
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Considering PTEN mutation or loss is a common aberration in human 
cancers, especially cancers with low survival rates such as glioblastoma 
multiforme, we sought to determine the role of the PTEN mutation PTENG129E in 
the U87MG glioblastoma model (Liu, James, Frederick, Alderete, & Jenkins, 
1997). A wild type PTEN, catalytically dead PTENC124S, and PTENG129E retroviral 
construct were used to generate U87MG and PTEN-/- MEFs cell lines. Wild type 
PTEN has functioning lipid phosphatase and protein phosphatase activity. 
PTENC124S encodes a PTEN mutant in which the catalytic cysteine is converted 
to a non-functioning serine, therefore rendering it completely lipid and protein 
phosphatase dead (Myers et al., 1997). Conversely, the PTENG129E mutant has a 
glycine to glutamic acid mutation, which makes it lipid phosphatase dead, but 
maintains protein phosphatase activity (Figure 7) (Myers et al., 1997). 
 cAMP response element-binding protein (CREB) is phosphorylated at 
serine 133 (RRPSYRK) by Akt and has shown to be dephosphorylated by PTEN 
(T. Gu et al., 2011). Similarly we tested if the Akt phosphorylation sites on Mdm2 
might also be dephosphorylated by PTEN (Figure 9). Using a phospho-antibody 
to serine 166 (RAISTEE) on Mdm2 the Akt phosphorylation site, which was 
observed in the phosphorylated state in response under Akt activation (Mayo & 
Donner, 2001).  We also tested another phosphorylation site on Mdm2, threonine 
218, to show PTEN was acing specifically at serine 166 on Mdm2 (T. Zhang & 
Prives, 2001).  Surprisingly, PTENG129E actually caused a robust increase in the 
phosphorylation at threonine 218 of Mdm2 in both U87 cells as well as in PC3 
cells, a prostate cancer cell line, while PTEN and PTENC124S did not show a 
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robust increase in the phosphorylation status at threonine 218 of Mdm2 (Figure 
10).  
Threonine 218 of Mdm2 has been reported to be phosphorylated by the 
Cyclin B/cdk1, mitosis-promoting complex (MPC) in murine cells (T. Zhang & 
Prives, 2001). The MPC complex is downregulated by Cdc25c and p27. When 
Cdc25c is dephosphorylated it is in its active conformation. Examination of 
phosphorylation state of Cdc25c showed dephosphorylation in the presence of 
PTENG129E. Examination by western blot  of p27, a cycle inhibitor, whose levels 
are important for blockade of cell cycle movement, were decreased in PTENG129E 
expressing cells (Figure 11 and 12, respectively)(Chu et al., 2007).  
To determine how PTENG129E may be influencing these cell cycle 
regulators we examine upstream regulator of Cdc25c, Checkpoint kinase 
1(Chk1). Chk1 inactivates Cdc25c through the phosphorylation of serine 216. 
Examination of the active state of Chk1 through the phosphorylation of serine 
317 showed that Chk1 was active in the PTENG129E cells (Figure 13)(Sanchez et 
al., 1997). We next determined if protein phosphatase 2A (PP2A), which is 
known to dephosphorylate Cdc25c, was active (Forester, Maddox, Louis, Goris, 
& Virshup, 2007). PP2A had no change in phosphorylation at tyrosine 307 
(Figure 14), when G129E was expressed. In addition we were unable to detect 
complex formation of G129E-PP2A complex. From these data, we concluded 
that G129E is regulating the cell cycle through other proteins and re-examined 
the role of p27 (Figure 15). 
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To assess if the cell cycle was active in G129E cells since they did have 
activated Cdc25c, flow cytometry cell cycle analyses were used.  Cells 
reconstituted with G129E show an increased percentage of cells in G2/M versus 
PTEN null cells, 45.6% and 15.4%, respectively (Figure 16). This observation 
suggests that cells with G129E fail to accumulate in G1/G0, and that loss of p27 
as an inhibitor of G1 could be causing this change. A time course study was 
conducted to examine the levels of cyclins in association with cell cycle 
movement.  Western blots of Cyclin A show rapid increases with G129E when 
serum is added back which was not evident in PTEN. The other cyclins did not 
show such robust increases (Figure 17). Therefore, the cells may be 
continuously dividing rather than pausing at G1/G0. G129E has a distinctly 
different cell cycle profile than wild type PTEN, catalytically dead C124S, and 
vector control in U87 cells. 
With the decreased levels of p27 shown by western blot in U87 cells 
transduced with G129E, and an increased proportion of cells in G2/M  we 
investigated the regulation  of p27 levels. As an inhibitor G1, it is heavily 
regulated by the tyrosine kinase Src. Under normal growth conditions, Src is an 
active kinase that can target p27 for phosphorylation, which inhibits its ability to 
bind cyclin dependent kinases, and eventually leads to p27 proteasomal 
degradation (Chu et al., 2007). Src is known for having both inhibitory and 
activating phosphorylation. Upon growth signaling, Src is targeted to the 
membrane where it is dephosphorylated at tyrosine 527, the inhibitory 
phosphorylation site. Then the activating autophosphorylation occurs at tyrosine 
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416, which accompanies a conformational change allowing Src to become an 
active kinase (Cooper, Gould, Cartwright, & Hunter, 1986; Irby & Yeatman, 2000; 
Okada & Nakagawa, 1988, 1989).  
First we determined that when G129E is present, p27 levels are 
decreased by western blot and decreases further under growth conditions 
(Figure 18). Furthermore, the presence of G129E is associated with a decrease 
in the inhibitory phosphorylation of Src, but had no effect on the Src. Similarly 
expression of wild type PTEN was also associated with a moderate decrease in 
inhibitory phosphorylation Src levels. Thus protein phosphatase activity and Src 
inactivating phosphorylation levels are associated (Figure 19). In addition 
bpV(HOpic) (a potent PTEN inhibitor) reversed the inhibitory phosphorylation that 
had been decreased to levels comparable to cells without G129E (Schmid et al., 
2004)(Figure 20). As similarly shown by Zhang et al who were able to precipitate 
a PTEN-Src interaction, we showed an immunoprecipitation of transduced Flag-
G129E by the flag tag resulted in precipitation of Src in both MEFs and U87 cells 
(Figure 21)(S. Zhang et al., 2011).  
Thus, G129E promotes cell cycle movement and may be considered a 
gain of function mutant through the downregulation of p27, and the activation of 
Cdc25. The modulation of cell cycle through Src and p27 may result in the 
increased tumorigenesis seen in mouse models and human patients.  
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TABLES 
 
Protein Phosphorylation  Sequence 
Cdc25C S216 RSPSMPE 
Chk1 S317 YSSSQPE 
Mdm2 T218 STGTPSN 
PP2A Y307 TPDYFL 
Src Y416 DNEYTAR 
Src Y527 EPQYQPG 
 
Table 1: Phosphorylation sites and sequences 
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FIGURES 
 
 
 
Figure 1: Cell cycle and regulators 
As growth factors increase, Rb begins to be hyperphosphorylated, and loses 
affinity to bind E2F. E2F is then free to transcribe cyclins necessary for the cell 
cycle. Particular cyclins and their cyclin dependent kinases increase levels then 
promptly decrease as the cell cycle progresses. Cyclin D and cyclin E are high in 
G1, Cyclin A is high in G2/S, and Cyclin B is high in M. CAK phosphorylates 
tyrosine 161 on CDK1 and he regulatory phosphatase Cdc25C dephosphorylates 
tyrosine 14 and 14 on CDK1 to initiate mitosis after interphase. The cell cycle 
inhibitor may inhibit CDK1/Cyclin B activity. 
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Figure 2: Src activation 
Src becomes activated when properly docked and dephosphorylated at tyrosine 
416 by SHIP. A conformational change of the SH2, SH3, and kinase domain 
causes an autophosphorylation at tyrosine 416 that renders the kinase domain 
active. 
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Figure 3: Src Inactivation 
In order for Src to be inactivate, CSk must bind the Src kinase domain. Then PTP 
can dephosphorylate tyrosine 416 and CSK can phosphorylate tyrosine 527. Src 
is then inactivated and returned to the closed conformation. 
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Figure 4: PTEN posttranslational modifications 
Ubiquitin can be conjugated onto Lysine 13. Sumoylation conjugation can 
happen at lysine 254 and 256. Either SUMO or Ubiquitin can be conjugated onto 
lysine 289. Acetlyation by PCAF can occur at lysine 125 and 128. CBP can 
acetylate PTEN at lysine 402. Phosphorylation at the C-terminal tail can occur at 
threonine 336 by GS3Kβ. CK2 can phosphorylate the C-terminal tail at serine 
370, serine 380, threonine 382, threonine 383, and serine 385. ATM can 
phosphorylate PTEN at serine 398. ROCK can phosphorylate PTEN at serine 
229, threonine 232, threonine 319, and threonine 321. Rak can phosphorylate 
PTEN at tyrosine 336. 
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Figure 5: Src, PI3K, and PTEN canonical pathway 
Src is a tyrosine kinase that can be activated by many membrane receptors 
including RTKs, IGF1-R, EGFR, and HER2/ERBB2. Src activates PI3K to 
phosphorylate PIP2 to PIP3. High concentrations of PIP3 allows recruitment of 
PDK and Akt to the membrane where they are activated to phosphorylate 
downstream survival and proliferative pathways. However, this pathway is 
inhibited by PTEN that dephosphorylates PIP2 leading to a decreased 
concentration of PIP3 at the membrane, and decreased active Akt at the 
membrane. 
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Figure 6: PTEN non-canonical functions 
PTEN under DNA damage conditions, can complex with p53 or p73 to transcribe 
apoptotic genes like puma and bax. 
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Figure 7: Mutations of the phosphatase domain 
Catalytically inactive PTENC124S and PTENG129E are located in the catalytic pocket 
of the phosphatase domain. 
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Figure 8: PTEN and mutants 
Phosphatase and tensin homolog (PTEN) is both a lipid and protein 
phosphatase. Mutant PTENC124S conversely has lost both protein and lipid 
phosphatase activity as a result of the mutation of the catalytic cysteine to serine. 
Mutant PTENG129E has retained protein phosphatase activity but lost lipid 
phosphatase activity.  
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Figure 9: PTEN targets CREB, but not Mdm2 
Akt phosphorylates CREB on serine 133, and PTEN dephosphorylates that site. 
Mdm2 has a similar Akt phosphorylation site on serine 166. PTEN does not 
dephosphorylate this site.  
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Figure 10: Mdm2 modulated when PTENG129E is expressed  
U87MG glioblastoma cells transduced with either null for PTEN (vector control), 
PTENwt, and PTENG129E were subjected to western blotting for PTEN, phospho-
Mdm2 Serine 218, activating phospho-Akt serine 473, total Akt and loading 
control GAPDH. PC3 Cells transduced with vector control (null for PTEN), 
PTENC124S, or PTENG129E were subjected to western blotting for phospho-Mdm2 
serine 218. 
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Figure 11: Cdc25c activity modulation by PTEN G129E 
U87 glioblastoma cells transduced with vector control, PTENwt, PTENC124S, or 
PTENG129E were subjected to western blotting for phospho-Cdc25c at serine 216 
levels and loading control GAPDH. 
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Figure 12: p27 levels in U87 cells with PTEN and mutants  
U87 glioblastoma cells transduced with vector control, PTENwt, PTENC124S, and 
PTENG129E were subjected to western blotting with p27 and loading control 
GAPDH. 
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Figure 13: Analysis of active Chk1  
U87 cells transduced with vector control, PTENwt, PTENC124S, or PTENG129E were 
subjected to western blotting for phospho-Chk1 at serine 317, and GAPDH.  
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Figure 14: PP2A phosphorylation and levels 
PTEN knockout MEFs and U87 cells were virally transduced with vector control, 
PTENwt, PTENC124S or PTENG129E. Lysates were subjected to western blotting for 
both phospho-PP2A at tyrosine 307, total PP2A, and loading control Actin. 
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Figure 15: Cell cycle regulation by PTENG129E through p27 or Cdc25c 
Schematic of mutant PTENG129E acting to propagate cell cycle through activity 
through two means: Direct activity on PP2A, leading to activation of Cdc25c, 
which directly activates the Cdk1/Cyclin B complex and then downstream 
phosphorylation of Mdm2 or an interaction associated with Src activation. Src 
phosphorylates p27 targeting it for further modification and eventual degradation 
at the 26S proteasome.  
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Figure 16: Cell cycle analysis of U87 cells 
Cell cycle analysis was performed on U87 glioblastoma cells transduced with 
vector control, PTENwt, PTENC124S, or PTENG129E. 
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Figure 17: Analysis of cyclin levels over a time course  
U87 cells transduced with PTENwt or PTENG129E were serum starved for 24 hours 
then subjected to replacement of serum for a time course of 0,4,6,8, and 24 
hours. Lysates were subjected to western blotting for Cyclin E2, Cyclin D1, Cyclin 
A2, Cyclin B1, and Actin. 
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Figure 18: Serum time course of p27 levels in U87 cell lines 
U87 cells transduced with vector control (null for PTEN), PTENG129E, PTENC124S, 
or PTENwt were subjected to a 24 hour serum starvation then serum was 
replaced for a time course of 0,4, or 6 hours. Lysates were then subjected to 
western blotting or p27 levels and loading control Actin. 
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Figure 19: Src levels and phosphorylation in PTEN mutants 
U87 cells transduced with vector control, PTENG129E, PTENC124S, or PTENwt were 
lysed and subjected to western blotting for total Src levels as well as the 
inhibitory phosphorylation of tyrosine 527 as well as the loading control Actin.  
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Figure 20: Analysis of Src phosphorylation with selective PTEN inhibitor 
U87 cells were treated with either DMSO or 2µM PTEN inhibitor, bpV(HOpic) for 
2 hours. Lysates were then subjected to western blotting for the inhibitory 
phosphorylation at tyrosine 527 and Actin.  
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Figure 21: Src and PTENG129E complex  
PTEN KO MEFs were transduced with Flag-PTENG129E and subjected to 
immunoprecipitation by Flag. Precipitates and whole cell lysates were subjected 
to western blotting for total Src and PTEN.  
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Figure 22: Combinational therapy approaches to combat resistance 
High resistance to trastuzumab (HER2 inhibitor) alone and in combination with 
tricibine (Akt inhibitor), lead to approaches of trastuzumab in combination with 
saracatinib (Src inhibitor. These approaches lead to the discovery of a PTEN and 
Src complex.  
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DISCUSSION 
 
Although PTEN has been classified as a tumor suppressor and its role as 
such is evident in disease states such as Cowden’s syndrome, we show here 
that PTEN could be considered an oncoprotein with a specific mutation in the 
catalytic domain, G129E. Previous literature has shown the protein phosphatase 
activity by PTENG129E (Myers et al., 1997). Knowledge of PTENG129E function was 
further expanded by Wang et al who showed increased tumor incidence in 
PTENG129E knockin mice (Wang et al., 2010). Furthermore we intended to gain a 
mechanistic understanding of signaling regulated by the gain of function 
PTENG129E. 
Due to the nature of the mutation being known for being lipid phosphatase 
dead but retaining protein phosphatase activity, it was hypothesized that 
PTENG129E could be functioning as a gain of function mutation through an 
additional protein target (Wang et al., 2010). The tumor suppressor mutation and 
association with tumor incidence gave clues as to how to investigate PTENG129E 
as a tumor suppressor with a gain of function mutation. Literature gives one 
example of an important gain of function mutation in p53. Certain mutations in 
p53 are associated with increased tumor incidence greater than that of merely 
loss of p53. It is hypothesized that these mutations allow p53 to transcribe 
additional targets that increase growth and chemotherapeutic resistance (Dittmer 
et al., 1993; Runnebaum, Kieback, Tong, & Kreienberg, 1993). Although p53 is a 
transcription factor, and PTEN is a phosphatase, we drew from these findings 
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that additional targets could be a means of a mutation gaining tumorigenic 
potential. 
Though efforts to deem Mdm2 or PP2A as direct protein targets were not 
possible, distinct cell cycle profile deviations pointed us into the direction of p27, 
a cell cycle inhibitor that had decreased levels in cells expressing PTENG129E. 
The cell cycle inhibitor, p27 has been considered a player in cancer and 
regulation of the cell cycle since the early 90’s. In addition it is inversely 
associated with poor prognosis in cancer patients (Esposito et al., 1997). 
Considering the cell cycle profile indicated that cells containing PTENG129E were 
not pausing in G1, modulation through a G1 inhibitor was plausible (Toyoshima & 
Hunter, 1994). Furthermore, p27 is regulated by the tyrosine kinase Src, and 
Cyclin E/CDK2 (Chu et al., 2007; Sheaff, Groudine, Gordon, Roberts, & Clurman, 
1997). 
Since Src has long been known to be an important kinase in cancers.  Src 
is a kinase that is activated upon growth signaling. When tyrosine 527 is 
phosphorylated and tyrosine 436 is not, Src is considered inactive. Conversely, 
when tyrosine 436 is phosphorylated and tyrosine 527 is not, the kinase is 
considered active (Dehm & Bonham, 2004). To determine if Src was playing an 
active role in the ability for PTENG129E to modulate the cell cycle we subjected to 
western blotting for Src phosphorylation using the phosphotyrosine 527 antibody, 
and saw decreased phosphorylation when G129E and wild type PTEN were 
present. Furthermore, when the PTEN inhibitor was used, the phosphorylation of 
inhibitory phospho-tyrosine increased. Conversely, Zhang et al showed that 
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PTEN could dephosphorylate Src at tyrosine 416 (activating site), while we show 
PTEN and PTENG129E modulating tyrosine 527 (inhibiting site)(S. Zhang et al., 
2011). Thus the functional implications of these data are opposing. 
Through immunoprecipitation of PTENG129E by Flag, Src was precipitated, 
which was corroborated with the finding by Zhang et al where wild type PTEN 
was precipitated with Src (S. Zhang et al., 2011). It is clear that an interaction is 
occurring both from our own findings in MEFs and U87 glioblastoma cells and 
from Zhang et al with BT474 breast cancer cells, but it is unclear what those 
interactions are doing and if a particular unknown condition also plays a role. Due 
to the resistance seen to trastuzumab both acquired and de novo, Zhang et al 
intended to find combinations of therapies that could combat this phenomena. 
Initially, the group tried to inhibit Akt since multiple receptors could be activating 
the Src/PI3K pathway. However, little effect was seen so the group inspected Src 
activity levels and realized that PTEN may be capable of inactivating Src. 
Through this discovery, the group inhibited Src in combination with trastuzumab 
to more effectively turn off the Src/PI3K pathway. Although they discovered the 
same interaction of PTEN and Src, they found Src modulating differently in 
response to the interaction. They show western blots with each PTEN mutant 
transduced inactivating Src when we show activation of Src. While our 
experiments were done in U87 glioblastoma cells in our laboratory, The Zhang 
laboratory did theirs in MDA-MB-468 cells. Therefor cell type specific signaling 
may be occurring.  Furthermore Src is not in completely inactive state with 
respect to phosphorylation in the publication. Activity of PTEN in the Zhang lab 
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only modulated the phosphorylation at tyrosine at 416, and the phosphorylation 
at tyrosine 527 was not returned to the inactive conformation. Further soft agar 
transformation experiments were done with SrcY527F(CA) and SrcK295R(DN) when 
they were never able to show this phosphorylation site’s state change 
with/without PTEN. These did show transformation, but don’t model the action of 
PTEN on Src, only Src on transformation(S. Zhang et al., 2011)(Figure 22).  
From our findings we conclude that PTENG129E forms a complex with Src 
and that may be responsible for the activation of Src. Subsequent decreases in 
p27 levels thereby allow cancerous cells to pass through the G1 checkpoint and 
continue such that FLOW cytometry captures G129E cells in G2/M. This 
modulation of the cell cycle through Src and p27 could be responsible for the 
increased number of tumors in mice with G129E and the increased cancer risk in 
human patients with the G129E mutation. Biochemically, in literature with the 
vast numbers of kinases responsible for oncogenic activity, it is unusual and 
unique to find a phosphatase that could be acting as an oncoprotein. 
In future experiments we intend to investigate further why our data differs 
from the Zhang et al, group examining in our own hands the phosphorylation 
levels at both sites on Src under expression of PTEN mutants in breast cancer 
cell lines, as well as in MEFs. We intend to see if PTEN inhibition will also 
increase p27 expression when G129E is expressed, showing a dependence of 
the cell cycle on G129E.   
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